An Institute for Socio Education Development & Education
  • 94311-14005


Thalassaemia is a chronic hereditary, hemolytic disease caused by faulty.

Hemoglobin Synthesis. It is a genetic blood disorder in which the bone marrow cannot form sufficient red cells and red cell survival is also reduced. A disorder that was thought of as untreatable in the earlier times is not so anymore, if managed and treated properly, patients can live fulfilling lives. The disease is widely spread in Mediterranean African and Asian countries.

Hemoglobin is a protein that is carried by red cells. It picks up oxygen in the lungs and delivers it to the peripheral tissues to maintain the viability of cells. Hemoglobin is made from two similar proteins that “stick together”. Both proteins must be present for the hemoglobin to pick up and release oxygen normally. One of the component proteins is called alpha, the other is beta. Before birth, the beta protein is not expressed. A hemoglobin protein found only during fetal development, called gamma, substitutes up until birth. The composition of hemoglobin is the same in all people. The genes that code for hemoglobin are identical throughout the world. Occasionally, however, one of the genes is altered by any of a variety of “accidents” that can occur in nature. These alterations in the genes (called “mutations”) are very rare. Since genes are inherited, and they contain the information needed to make a protein, if a mutation produces an abnormal hemoglobin gene in a person, the gene will be passed on to his or her children. The children will produce modified hemoglobin identical to that of the parent. Most mutations in hemoglobin produce no problem. Occasionally, however, the alteration in the protein changes aspects of its behavior. The types of disorders that can result include sickle cell disease and Thalassaemic.

Genes can suffer damage to an extent that they no longer produce normal amounts of hemoglobin. Usually, only one of the sets of hemoglobin genes is affected, that is the alpha gene set or the beta gene set. For example, one of the two beta globins genes may fail to produce a normal quantity of beta chain protein. The alpha globins gene set will continue to produce a normal quantity of alpha chain protein. An imbalance develops in the amount of alpha chain and beta chain that is present. This imbalance is called “Thalassaemia”.

The genes involved in Thalassaemia control the production of a protein in red cells called hemoglobin. Hemoglobin binds oxygen in the lungs and releases it when the red cells reach peripheral tissues, such as the liver. The binding and releases of oxygen by hemoglobin is essential four subunit proteins. Two of the subunit proteins are called alpha and two are called beta. Hemoglobin properly binds and releases oxygen only when two alpha subunits are connected to two beta subunits. A pair of genes located on chromosome 16 controls the alpha subunits of hemoglobin. A single gene located on chromosome 11 controls the production of the hemoglobin beta subunit.

This is one of the most challenging diseases being faced by mankind with virtually no permanent treatment for those who suffer from it. The only real treatment is periodical replenishment of blood through transfusion.

We are working very hard on this disease. So far there has been a limited success and two distinct treatment strategies have been designed. We have found these to work on a good percentage of cases. However, though this percentage is small it is infinitely better than what is available from conventional medicine where there are virtually no successes to show.

As can be seen from the citing the patient's need for blood transfusion has gradually diminished and ultimately stopped. At the same time the patient's Hemoglobin count gradually rose and allowed him/her to lead a normal life.

Prevention of Thalassemia in India

Thalassemia syndromes are a heterogeneous group of single gene disorders, inherited in an autosomal recessive manner, prevalent in certain parts of the world(1). Worldwide, 15 million people have clinically apparent thalassemic disorders. Reportedly, there are about 240 million carriers of β-thalassemia worldwide, and in India alone, the number is approximately 30 million with a mean prevalence of 3.3%(2,3). They are encountered among all ethnic groups and in almost every country around the world.

Every year approximately 100,000 children with Thalassemia Major are born world over, of which 10,000 are born in India. It is estimated that there are about 65,000-67,000 β-thalassemia patients in our country with around 9,000-10,000 cases being added every year(1-7). The carrier rate for β-thalassemia gene varies from 1 to 3% in Southern India to 3% to 15% in Northern India. Certain communities in India, such as Sindhis and Punjabis from Northern India, Bhanushali’s, Kutchis, Lohana’s from Gujarat, Mahar’s, Neobuddhist’s, Koli’s and Agri’s from Maharashtra, & Gowda’s and Lingayat’s from Karnataka etc. have a higher carrier rate(3,4).

Once a child is diagnosed to have thalassemia homozygous disorders, he/she has to take lifelong treatment. Management includes regular 3 weekly filtered packed red cell transfusions, chelation therapy for iron overload, management of complications of iron overload and transfusions, including osteoporosis, cardiac dysfunction, endocrine problems, Hepatitis B & C, HIV infection, CMV etc. However, this optimal treatment comes at a prohibitive cost. The cost of treatment of an average weight 4-year-old thalassemic child is around Rs. 90,000-100,000 annually in a private set-up. Therefore, not more than 5-10% of thalassemic children born in India receive optimal treatment. Stem cell transplantation as a curative treatment, which costs between 6 and 16 lac rupees is out of reach for majority of children.

Besides bearing the cost of treatment, the psychological stress to both the patient and the parents/family is phenomenal. In fact, it is startling to know from a 15 year old thalassemic child the account of what he has undergone so far. He has received around 250 units of packed red cells and 4000 injections of desferioxamine. He has had a needle in his body for over 40,000 hours of his life. His family has already spent Rs. 16,20,000 for chelation alone. If this child lives for 50 years, then he would require 2000 units of packed red cells, 15,000 desferrioxamine injections, which translates into 1.5 lac hours of a needle in his body and Rs 90 lacs for chelation alone (personal communication). This is besides the cost incurred by the hospital where he receives his regular treatment including packed red cell transfusions and other medical care.

The birth of a thalassemic child thus places considerable strain not only on affected child and family but on society at large. Therefore there is emphasis for shift from treatment to prevention of birth of such children in future. This can be achieved by:

Population education

Mass screening of high risk communities for thalassemia minor

Genetic counseling of those who test positive for thalassemia minor

Prenatal Diagnosis

The question that arises in the mind is whether prevention at a national level is cost-effective. The answer to this is Yes, it is cost-effective and we should strive to prevent the birth of a thalassemic child. In a study done in Iran, it was concluded that the ratio of cost of treatment to prevention of thalassemia is 16:1.6 (5). A similar result was published by Ostrowsky et al. (6) from Quebec, Canada. They found that the total cost per case prevented was less than the cost of a single year of treatment for an individual with the disease. Further, they found that with current rates of marriage and endogamy, the costs that would accrue by having to treat individuals with thalassemia were more than twice those incurred by the delivery of the prevention program. A World Health Organization committee, in a study, stated that in Cyprus, the annual cost of running the screening and prenatal diagnosis program was found to be about equal to the cost of treatment of all existing patients for five years. In Sardinia, the committee estimated that a 90 per cent reduction in the incidence of thalassemia disease would recoup the cost of setting up a prevention program in three years from the start of the services; thereafter the total cost of treatment would fall steadily over the next five years to about one-fifth of the projected cost of treatment

Prevention of thalassemia, therefore is practical, feasible and the answer to the agony of so many children, families and nations. The methods would include creating awareness amongst high risk communities about the prevalence and the difficulties in management of this condition. Screening young people amongst all high risk communities before marriage is the right way to go. If screening is performed in childhood, it is often forgotten around the time they get married. Hemoglobin electrophoresis is the confirmatory test to diagnose thalassemia minor or carrier status. All at-risk couples need to be counseled about the prenatal diagnosis to confirm the thalassemic status of the fetus. If the fetus is not affected, the pregnancy should be continued. If the fetus is affected, the choice of terminating the pregnancy is offered.

A concerted effort is needed to have a National Thalassemia Prevention Program in place. This needs involvement of all government health agencies, scientific research bodies, institutions caring for thalassemia, parents’ societies, dedicated and committed social workers along with the medical fraternity to be able to successfully eradicate thalassemia from the country. With this in mind Indian Academy of Pediatrics has envisaged Thalassemia Prevention Program under IAP Vision 2007. A national consultative meeting is planned this year to formulate the guidelines for an ideal thalassemia prevention program which will be followed by a series of advocacy and sensitization meetings in high risk states. If countries like Cyprus, Sardinia and Greece could achieve, there is no reason why we cannot achieve the same.

Our Programme will be conducted in three stages

Prevensation (Awareness Programme)

Life long treatment (Blood Transfussion)

Curative treatment (Transplantation)

Implementation of the project. C.ED. is having a complete infrastructure.

Team of Doctors under its medical cell.

Skilled manpower.

Competent management

Land 5 Acres approx at Latehar and 1 Acre Approx at Ranchi.

Experience in health related programme for last 12 years i.e 58 Nos. Blood Donation camps more then 50 Nos. Health check up camps about 10 tubertomy and vaccitomy operation, several thalassaemia related seminars and AIDS related seminars/workshops in all over the state.